anti-c-Met monoclonal antibodies (Sorrento Therapeutics)

N/A

Report date: 2025/06/11 11:16:44

Base Information

Drug Nameanti-c-Met monoclonal antibodies (Sorrento Therapeutics)
Drug Alias Nameanti-c-Met mAbs (Sorrento Therapeutics)STI-A0602STI-A0601STI-A0603STI-A060X
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnticancer protein kinase inhibitorsHepatocyte growth factor receptor inhibitors
TargetsHepatocyte growth factor receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSorrento Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSorrento Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A